Regulatory Responses: Warnings at Last In June 2025 , the European Medicines Agency (EMA) concluded that NAION should be listed as a very rare side effect of semaglutide medications
Depression, Complicated Grief (00:12:20) Stages of Grief, Individual Variation for Grieving (00:16:05) Grief: Lack & Motivation, Dopamine (00:23:15) Three Dimensions of Relationships (00:29:52) Tool: Remapping Relationships (00:37:15) Grief, Maintaining Emotional Closeness & Remapping (00:44:40) Memories of Loved Ones & Remapping Attachments (00:48:04) Yearning for Loved Ones: Memories vs
Central to the plaintiffs argument is the claim that these medications cause gastroparesis, while the defense contends that the drugs are designed to delay gastric emptying, which they argue is distinct from gastroparesis
By reducing ones appetite and slowing the digestive process, Semaglutide makes it easier to follow a new way of eating, which can help clients lose up to five pounds per month with weekly injections
That access discussion should stay separate from the medical decision about whether semaglutide is appropriate